Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Inclusion Criteria:

• 18 years of age

• Histology: pathologically documented, KRAS G12C-mutated, advanced or metastaticsolid tumors not amendable to curative therapy

1. Phase 1b Dose Escalation: solid tumors, previously treated

2. Phase 1b Dose Expansion and Phase 2: i. NSCLC, previously treated with immunotherapy, chemotherapy, and KRAS G12C (OFF)inhibitors ii. Solid tumors, previously treated, naïve to KRAS G12C (OFF)inhibitors.

• ECOG performance status 0 or 1

• Adequate organ function

Exclusion Criteria:

• Primary central nervous system (CNS) tumors

• Active brain metastases

• Known impairment of GI function that would alter the absorption

• Major surgical procedures within 28 days or non-study related minor procedureswithin 7 days of treatment